Page, Ray

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Changing Physician Incentives for Affordable, Quality Cancer Care: Results of an Episode Payment Model

Newcomer, L. N., Gould, B., Page, R. D., Donelan, S. A., & Perkins, M. (2014) · Journal of Oncology Practice

Healthcare Policy and ManagementEconomic and Financial Impacts of Cancer

Cited by 128

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H., & Renschler, M. F. (2013) · Annals of Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 108

Opioids and cancer pain: patients' needs and access challenges

Page, R., & Blanchard, E. (2019) · Journal of Oncology Practice

Pain Management and Opioid UseOpioid Use Disorder Treatment

Cited by 83

Reducing Cancer Costs Through Symptom Management and Triage Pathways

Barkley, R., Soobader, M.-J., Wang, J., Blau, S., & Page, R. D. (2019) · Journal of Oncology Practice

Economic and Financial Impacts of CancerEmergency and Acute Care Studies

Cited by 25